Stoke Therapeutics Inc (STOK) Beta Value: Understanding the Market Risk

1d ago, source: newsheater

Nash Huw M., the COO & CBO of Stoke Therapeutics Inc, sale 61,329 shares at $13.23 during a trade that took place back on Apr 01 ’24, which means that Nash Huw M. is holding 0 shares at $811,212 based ...

Stoke Therapeutics raises upsized $125M public offering on heels of Dravet trial results

29d ago, source: The Business Journals

With shares of Stoke Therapeutics Inc. trading at its highest level since October 2022, the biotech is planning a public offering. After first announcing on Wednesday that it aimed to sell up to $ ...

Why Stoke Therapeutics Shares Are Trading Higher By Around 70%; Here Are 20 Stocks Moving Premarket

1mon ago, source: Business Insider

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) rose sharply in today’s pre-market trading after the company announced Phase 1/2a data supporting the potential for STK-001 in Dravet syndrome.

Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer

8d ago, source:

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe ...

Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering

28d ago, source: Nasdaq

BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein ...

Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Lags Revenue Estimates

1mon ago, source: Nasdaq

Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to loss of $0.65 per share a year ago.

Stoke Therapeutics Inc STOK

8d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

What's Going On With Stoke Therapeutics Stock Tuesday?

1mon ago, source: Benzinga.com

Stoke Therapeutics announces a proposed underwritten public offering of up to $75 million of its common stock. Stoke Therapeutics shares close Tuesday up more than 58%. The stock is up another ...

Stoke Therapeutics Inc’s (STOK) Stock: A Long-Term Performance Analysis

16d ago, source: newsheater

Based on Stoke Therapeutics Inc (STOK), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -39.31. The debt to equity ratio ...

Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering

29d ago, source: Stockhouse

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today ...